Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling

• Main Authors: Annie Moisan (Author), Marcel Gubler (Author), Jitao David Zhang (Author), Yann Tessier (Author), Kamille Dumong Erichsen (Author), Sabine Sewing (Author), Régine Gérard (Author), Blandine Avignon (Author), Sylwia Huber (Author), Fethallah Benmansour (Author), Xing Chen (Author), Roberto Villaseñor (Author), Annamaria Braendli-Baiocco (Author), Matthias Festag (Author), Andreas Maunz (Author), Thomas Singer (Author), Franz Schuler (Author), Adrian B. Roth (Author)
• Format: Book
• Published: Elsevier, 2017-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Antisense oligonucleotide (AON) therapeutics offer new avenues to pursue clinically relevant targets inaccessible with other technologies. Advances in improving AON affinity and stability by incorporation of high affinity nucleotides, such as locked nucleic acids (LNA), have sometimes been stifled b...